Modulation of myelopoiesis by three synthetic muramyl peptides was investigated in vivo. Two adjuvant-active compounds (N-acetylmuramyl dipeptide [MDP] and MDP-butyl-ester) elicited significant responses in DBA/2 mice characterized by a rise in the level of monocyte-macrophage colony-stimulating activity in serum, a proliferation of multipotential stem cells in the bone marrow, and an expansion of granulocyte-macrophage progenitors in the spleen. In contrast, the adjuvant-inactive stereoisomer MDP(D-D) induced only low levels of circulating colony-stimulating activity. Thus, MDP or MDP-butyl-ester injection could induce a greater number of macrophages and therefore enhance both specific and nonspecific immunity.
Modulation of myelopoiesis by three synthetic muramyl peptides was investigated in vivo. Two adjuvant-active compounds (N-acetylmuramyl dipeptide [MDP] and MDP-butyl-ester) elicited significant responses in DBA/2 mice characterized by a rise in the level of monocyte-macrophage colony-stimulating activity in serum, a proliferation of multipotential stem cells in the bone marrow, and an expansion of granulocyte-macrophage progenitors in the spleen. In contrast, the adjuvant-inactive stereoisomer MDP(D-D) induced only low levels of circulating colony-stimulating activity. Thus, MDP or MDP-butyl-ester injection could induce a greater number of macrophages and therefore enhance both specific and nonspecific immunity.
Considerable evidence has implicated the monocyte-macrophage as the target cell for the mediation of the effects of N-acetylmuramyl dipeptide (MDP), a synthetic adjuvant (1, 6, 9, 12) . However, the exact mechanism by which MDP exerts its enhancement of macrophage activities remains unclear (9) . Modulation of myelopoiesis may play a major role in the host response. The question arises as to whether MDP stimulates the proliferation of progenitor cells in the bone marrow, leading to increased numbers of mononuclear cells and thereby to an increased efficiency of the reticuloendothelial system (19, 22) . Indications for such a mechanism have been obtained in vivo, where MDP injection induced monocytosis (7) , and in vitro, where stimulation of peritoneal macrophages by MDP induced high levels of colony-stimulating activity (CSA) (17) .
We report here studies designed to further elucidate the action of MDP on in vivo hematopoiesis by assessing its effects on the induction of serum CSA and on multipotential (CFU-S) and committed (GM-CFC) hematopoietic stem cells. Many derivatives of MDP have been synthesized, and some have been shown to be devoid of pyrogenicity although they retained their immunostimulant properties. In the present study, the activity of one such derivative, MDPbutyl-ester (5), was compared with that of MDP and that of its adjuvant-inactive stereoisomer, (10) . The nonpyrogenic MDP derivative N-acetylmuramyl-L-alanyl-Dglutamine-a-n-butyl-ester or MDP(Gln)-OnBu, was synthesized by Lefrancier et al. (11) . Lipopolysaccharide (LPS) prepared by the phenol-water procedure from Salmonella enteritidis was purchased from Difco Laboratories (Detroit, Mich.). All MDP-butyl-ester was as active as MDP, and, as observed with MDP, the optimal effect was found with a dose of 5 mg/kg. However, the kinetics of CSA induction was different, the peak value of serum CSA being reached after 18 h. In contrast, MDP(D-D) induced a low level of serum CSA at doses examined (0.5, 5, and 50 mg/kg). Serum of saline-treated mice showed weak activity which was not modified if the glycopeptides were admixed in different concentrations (10 ng/ml to 100 jig/ml) before the colony assay was performed.
Morphological analysis of the cell colonies induced by serum CSA. The cell colonies induced by CSA in the cultures were stained in situ after dessication of the agar plates. Sera from mice injected with 5 mg of glycopeptides per kg were compared with post-LPS serum. Sera were obtained at the peak value of serum CSA. It was observed ( 
DISCUSSION
In the present study, modulation of myelopoiesis by three synthetic glycopeptides was examined. MDP and MDP-butyl-ester elicited a significant in vivo hematopoietic response. This was evidenced by changes in several parameters, including a rise in the level of monocytemacrophage CSA in serum, a proliferation of multipotential stem cells in the bone marrow, and an expansion of granulocyte-macrophage progenitors in the spleen. All these properties were shared equally by the two active compounds. In contrast, the adjuvant-inactive stereoisomer MDP(D-D) induced only low levels of circulating CSA. The nature of the CSA induced may explain why blood neutrophil counts do not change after MDP injection, whereas blood monocyte counts are increased (7, 24) . Indeed, the population of colonies induced by the serum of MDP-or MDP-butyl-ester-treated mice was composed of 81% monocyte-macrophage colonies and of only 5 to 6% granulocyte colonies. As judged by their pattern of stimulation, these glycopeptides induced CSA similar to that produced in L-cell-conditioned medium, a predominantly macrophage colony stimulus (16, 18) . Furthermore, as was previously shown by Limulus lysate assays (5, 14) , contamination of the synthetic compounds with LPS can be excluded on the basis of their distinct CSA, which clearly sets them apart from each other. MDP and MDP-butyl-ester induced a monocyte-macrophage CSA which differs from the granulocytemacrophage CSA produced by LPS (13, 15) . Further investigations are necessary to explain the effect of MDP and MDP-butyl-ester on CFU-S. The apparent increase in femoral CFU-S 24 h after glycopeptide injection could be due to a change in the absolute numbers of CFU-S or in the self-renewal capacity of these cells. The determination of the effect of glycopeptides on the cell cycle status and on the splenic seeding efficiency of these cells should help to resolve this question.
The mechanism underlying the increase of spleen GM-CFC after administration of glycopeptides is not clear. As was previously observed (21), MDP did not induce proliferation of GM-CFC in vitro. Furthermore, it did not enhance growth of GM-CFC induced by normal serum in vitro. The same is true for MDP-butylester. This, in combination with the fact that the glycopeptides induced proliferation of CFU-S and release of CSA, supports the view that the rise in splenic GM-CFC could be the expression of a direct effect of glycopeptides on the proliferation and differentiation of CFU-S and of an indirect effect via CSA on proliferation and differentiation of GM-CFC. Furthermore, other mechanisms, such as self-replication of splenic GM-CFC or migration of GM-CFC from the bone marrow, can by no means be excluded. Glycopeptides may cause an increase of GM-CFC by partially different mechanisms. Moreover, as was previously observed with different cell wall components from gram-negative bacteria (17) , no quantitative correlation was observed between CSA induction and increase in splenic GM-CFC. MDP(D-D) induced some serum CSA but failed to increase the number of splenic GM-CFC.
These findings are compatible with those of Staber et al. (17) who have shown that CSA release could be induced in vitro by peritoneal macrophages stimulated by MDP. In contrast, these results are the reverse of those found by Wuest and Wachsmuth (24) when they administered MDP subcutaneously to mice. Under this condition, they observed an increase in bone marrow GM-CFC but found no enhancement of serum CSA or of spleen and peritoneal cavity GM-CFC. They suggest that GM-CFC level in the bone marrow may rise as an effect of MDP on myeloid progenitor cells or alternatively as an effect on an unidentified effector cell which in turn stimulates recruitment or proliferation of myeloid progenitor cells. This difference in results is probably due to the sensitivity of the colony assay: we have obtained ca. modification in the number of bone marrow GM-CFC after glycopeptide injection, probably because of the large variation in the number of bone marrow GM-CFC in our controls.
In conclusion, a consequence of CSA release and of proliferation of CFU-S and GM-CFC could be the availability of greater numbers of macrophages able to process antigen, thereby regulating humoral immune responses, or able to enhance nonspecific resistance to infection (4, 5) . Agents such as MDP and MDP-butyl-ester may, therefore, be of use in cases where monocytosis is desirable.
